Methyl aminolevulinate-photodynamic therapy for basal cell carcinoma

Szeimies, Rolf-Markus (2007) Methyl aminolevulinate-photodynamic therapy for basal cell carcinoma. DERMATOLOGIC CLINICS, 25 (1). 89-+. ISSN 0733-8635,

Full text not available from this repository. (Request a copy)

Abstract

Basal cell carcinomas (BCCs) are the most common malignant tumors of the skin. Treatment of BCCs should be chosen according to clinical type, tumor size, and location. Methyl aminolevulinate (MAL) photodynamic therapy (PDT) has the potential to become a therapy with equal effectiveness to classical therapeutic modalities with an excellent cosmesis, but without complications like scar formation, requirement for grafts, need of repetitive treatments over longer time periods, or pigmentary changes. MAL is licensed in Europe, Australia, New Zealand, and Brazil for the treatment of actinic keratoses, Bowen's disease, and nodular and superficial BCC. Conclusions are drawn from extensive studies in past years using MAL-PDT for both nodular and superficial BCCs.

Item Type: Article
Uncontrolled Keywords: ACID; TUMORS;
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Dermatologie und Venerologie
Depositing User: Dr. Gernot Deinzer
Date Deposited: 12 Jan 2021 06:04
Last Modified: 12 Jan 2021 06:04
URI: https://pred.uni-regensburg.de/id/eprint/33396

Actions (login required)

View Item View Item